• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Fusion biopsy: A view from the trenches



Like many U.S. urologists, I have been intrigued by the wealth of articles and presentations by urology’s academic leaders on the use of magnetic resonance imaging-ultrasound fusion targeted biopsies in prostate cancer. In fact, one of my goals at the 2016 AUA annual meeting was to learn more about this potentially game-changing technology.

Read: Single-payer proposals crop up at state, federal level 

My conclusion? Jay Bishoff, MD, the proctor at a plenary session on fusion biopsy, nailed it when he stated that MRI fusion biopsy was the future of prostate biopsy; it’s just not quite prime time yet. The data behind its use in the setting of a rising PSA after a negative biopsy is impressive, but I’m unsure how a small practice justifies the six-figure cost when there is no reimbursement for it.

Related: Increased use of telehealth prompts heightened legislative activity 

I also am not sold on its use on first-time biopsy patients, although I concede that the ability to get an MRI after the fact and then fit your biopsy tracts onto the image to see if you missed a suspicious area is fascinating. I also can see how a large, vertically integrated system such as a university would love the technology because if it increases the use of MRIs and increases the number of biopsy specimens being done, that certainly would defray the cost of the machine.

Next: MRI-Targeted Prostate Biopsy


As for me, I intend to follow the white paper that was introduced at the AUA (“MRI-Targeted Prostate Biopsy After Prior Negative Biopsy: An SAR-AUA Consensus Statement”), which allows for cognitive fusion to be used for now. If and when the AUA changes its opinion on the technology, I likely will too.

Also see: States address payer interference with physicians' orders

On a different note, one of the more intriguing concepts that came out of my AUA courses on fusion biopsy was an attendee question at Eric Klein, MD’s course on new diagnostics for prostate cancer. The attendee asked if it was appropriate to move straight to definitive treatment simply based on a PI-RADS 5 lesion on prostatic MRI. I thought this was a great question because if the accuracy of prostatic MRI approaches 80% to 90% for clinically significant cancer in a PI-RADS 5 lesion, that is similar to the accuracy of a contrast-enhanced CT for renal masses and no one would fault me for removing a 5-cm enhancing renal mass without biopsy, would they?

So why can’t I remove a prostate for a PI-RADS 5 lesion on prostatic MRI? A question for my academic friends.


More from Urology Times

Bills provide relief from meaningful use requirements 

Urology's advocacy priorities: One down, four to go

The fate of SGR repeal rests with the Senate 


Related Videos
Samuel L. Washington III, MD, MAS, answers a question during a Zoom video interview
Human kidney cross section on scientific background | © Crystal light - stock.adobe.com
Leo Dreyfuss, MD, answers a question during a Zoom video interview
Neal Shore, MD, FACS, and Brian M. Shuch, MD, experts on kidney cancer
Neal Shore, MD, FACS, and Brian M. Shuch, MD, experts on kidney cancer
Conceptual image for prostate cancer treatment | © Dr_Microbe - stock.adobe.com
David Gilbert answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.